Methodology | Antifungal | No. | MIC50 | MIC90 | Susceptible | Resistant | |
---|---|---|---|---|---|---|---|
(µg/mL) | (µg/mL) | (%) | (%) | 95% CI | |||
CLSI | Caspofungin | 33 | 0.5 | 0.5 | 100.0 | 0.0 | 0.0–10.6 |
Breakpoints | Micafungin | 29 | 1 | 2 | 100.0 | 0.0 | 0.0–11.9 |
Fluconazole | 33 | 0.5 | 1 | 100.0 | 0.0 | 0.0–10.6 | |
Voriconazole | 33 | 0.008 | 0.015 | 100.0 | 0.0 | 0.0–10.6 |
No. | MIC50 | MIC90 | WT1 | NWT2 | 95% CI | ||
---|---|---|---|---|---|---|---|
(µg/mL) | (µg/mL) | (%) | (%) | ||||
CLSI | Amphotericin B | 33 | 0.5 | 0.5 | 100.0 | 0.0 | 0.0–10.6 |
ECV3 | Posaconazole | 15 | 0.03 | 0.06 | 100.0 | 0.0 | 0.0–21.8 |